NCT06827457View on ClinicalTrials.gov

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

PHASE1RecruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

January 21, 2026

Study Completion Date

April 28, 2026

Conditions

Autoimmune Disease

Interventions

DRUG

GenSci120

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

20040

RECRUITING

Huashan Hospital, Shanghai

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY